当前位置: 首页 > 详情页

Fisetin Alleviates Lipopolysaccharide-Induced Acute Lung Injury via TLR4-Mediated NF-kappa B Signaling Pathway in Rats

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, 221002, People’s Republic of China [2]Department of Anesthesiology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People’s Republic of China [3]Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical College, Xuzhou, 221002, People’s Republic of China [4]Department of Anesthesiology, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, People’s Republic of China
出处:
ISSN:

关键词: acute lung injury acute respiratory distress syndrome fisetin lipopolysaccharide Toll-like receptor 4 NF-kappa B

摘要:
Acute lung injury (ALI), a common component of systemic inflammatory disease, is a life-threatening condition without many effective treatments. Fisetin, a natural flavonoid from fruits and vegetables, was reported to have wide pharmacological properties such as anti-inflammatory, antioxidant, and anticancer activities. The aim of this study was to detect the effects of fisetin on lipopolysaccharide (LPS)-induced acute lung injury and investigate the potential mechanism. Fisetin was injected (1, 2, and 4 mg/kg, i.v.) 30 min before LPS administration (5 mg/kg, i.v.). Our results showed that fisetin effectively reduced the inflammatory cytokine release and total protein in bronchoalveolar lavage fluids (BALF), decreased the lung wet/dry ratios, and obviously improved the pulmonary histology in LPS-induced ALI. Furthermore, fisetin inhibited LPS-induced increases of neutrophils and macrophage infiltration and attenuated MPO activity in lung tissues. Additionally, fisetin could significantly inhibit the Toll-like receptor 4 (TLR4) expression and the activation of NF-kappa B in lung tissues. Our data indicates that fisetin has a protective effect against LPS-induced ALI via suppression of TLR4-mediated NF-kappa B signaling pathways, and fisetin may be a promising candidate for LPS-induced ALI treatment.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 3 区 医学
小类 | 4 区 细胞生物学 4 区 免疫学
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 细胞生物学 3 区 免疫学
JCR分区:
出版当年[2014]版:
Q3 CELL BIOLOGY Q3 IMMUNOLOGY
最新[2023]版:
Q2 CELL BIOLOGY Q2 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者机构: [1]Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, 221002, People’s Republic of China
通讯作者:
通讯机构: [*1]Department of Anesthesiology, Beijing Shijitan Hospital, Capital Medical University, Beijing ,100038 , People's Republic of China .
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院